(TXR 013599) (8-3-99) 15

EPA Reviewer: Irving Mauer, Ph.D. Date: _____
Toxicology Branch 2, Health Effects Division (7509C)
EPA Secondary Reviewer: Ching-Hung Hsu, Ph.D. Date: _____
Toxicology Branch 2, Health Effects Division (7509C)

DATA EVALUATION RECORD

STUDY TYPE: Salmonella and Escherichia/mammalian activation gene mutation assay; OPPTS 870.5100 [84-2]

DP BARCODE: D243979 SUBMISSION CODE: S538757

P.C. CODE: 129112 TOX. CHEM. NO.: [N/A]

MRID NO.: 44496716

TEST MATERIAL (PURITY): CGA-373466 technical (metabolite of trifloxystrobin; 99%)

SYNONYMS: [None]

CITATION: Deparade, E. (1997). Salmonella and Escherichia/Mammalian-Microsome Mutagenicity Test, conducted at the Genetic toxicology Laboratory of Novartis Corp Protection AG, Basle (Switzerland, Test No. 973025 (Novartis Nexus Number 708-97), dated September 16, 1997. MRID 44496716. Unpublished.

EXECUTIVE SUMMARY: In a reverse gene mutation assay in bacteria (MRID No. 4496716), triplicate cultures of Salmonella typhimurium strains TA98, TA100, TA102, TA1535, TA1537 and Escherichia coli strain WP2 *uvr*A were exposed in two trials to CGA-373466 (99%) in acetonitrile at five concentrations ranging from 312.5 to 5000 *u*g/plate in the presence and absence of a metabolic activation system consisting of the post-mitochondrial (S9) fraction of Arochlor 1254-induced male rat liver. In addition to solvent controls, additional cultures were treated with strain-specific mutagens as positive controls. After 48 hours incubation at 37 degrees C, the frequency of revertant colonies in test cultures was compared to solvent controls. Nonstatistical analysis criteria (1.5X or 2X fold) were used to define a positive response.

In no strain at any concentration of test article was an increase over negative controls in the incidence of revertant colonies observed, in contrast to the strong positives found in all mutagen-treated cultures.

This study is classified as acceptable and satisfies the requirement for FIFRA Test Guide 84-2 for *in vitro* mutagenicity (bacterial reverse gene mutation) data.

COMPLIANCE: Signed and dated GLP, Quality Assurance, and Data Confidentiality statements were provided.

NB: This EPA-generated Executive Summary agrees with the attached summary and conclusions of the 6/4/98 dated CALEPA Toxicology Study Evaluation Worksheet for the same study.

A:\triflox.16

SignOff Date:	8/3/99
DP Barcode:	D243979
HED DOC Number:	013599
Toxicology Branch:	TOX2